Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01592370 · OUTCOME

Number of Participants With PD-L1 Expression

An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma · Source last updated 2025-10-22

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
Number of Participants
Interval / dispersion
Not reported
Time frame
At baseline (prior to start of study treatment)

What was measured

Number of Participants with PD-L1 expression in the following categories * baseline PD-L1 expression ≥ 1% * baseline PD-L1 expression \< 1% * without PD-L1 quantifiable at baseline

Analysis population: All Treated Participants

Groups in this outcome

Nivolumab Monotherapy (Expansion)

3mg/kg of nivolumab

Nivolumab + Ipilimumab

3 mg/kg of nivolumab and 1 mg/kg of ipilimumab Q3W for 4 doses, followed by nivolumab alone at 3 mg/kg Q2W

Nivolumab + Lirilumab

3 mg/kg of nivolumab Q2W + 3 mg/kg of lirilumab Q4W

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Nivolumab Monotherapy (Expansion)105
Nivolumab + Ipilimumab65
Nivolumab + Lirilumab72

Reported measurements

Baseline PD-L1 expression ≥ 1%
Values in Number of Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Nivolumab Monotherapy (Expansion)25Not reportedNot reportedNot reportedNot reported
Nivolumab + Ipilimumab26Not reportedNot reportedNot reportedNot reported
Nivolumab + Lirilumab16Not reportedNot reportedNot reportedNot reported
Baseline PD-L1 expression < 1%
Values in Number of Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Nivolumab Monotherapy (Expansion)16Not reportedNot reportedNot reportedNot reported
Nivolumab + Ipilimumab14Not reportedNot reportedNot reportedNot reported
Nivolumab + Lirilumab20Not reportedNot reportedNot reportedNot reported
PD-L1 not quantifiable at baseline
Values in Number of Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Nivolumab Monotherapy (Expansion)64Not reportedNot reportedNot reportedNot reported
Nivolumab + Ipilimumab25Not reportedNot reportedNot reportedNot reported
Nivolumab + Lirilumab36Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        25
      2. group Id
        OG001
        value
        26
      3. group Id
        OG002
        value
        16
    title
    Baseline PD-L1 expression ≥ 1%
  2. categories
    1. measurements
      1. group Id
        OG000
        value
        16
      2. group Id
        OG001
        value
        14
      3. group Id
        OG002
        value
        20
    title
    Baseline PD-L1 expression < 1%
  3. categories
    1. measurements
      1. group Id
        OG000
        value
        64
      2. group Id
        OG001
        value
        25
      3. group Id
        OG002
        value
        36
    title
    PD-L1 not quantifiable at baseline
denoms
  1. counts
    1. group Id
      OG000
      value
      105
    2. group Id
      OG001
      value
      65
    3. group Id
      OG002
      value
      72
    units
    Participants
description
Number of Participants with PD-L1 expression in the following categories * baseline PD-L1 expression ≥ 1% * baseline PD-L1 expression \< 1% * without PD-L1 quantifiable at baseline
groups
  1. description
    3mg/kg of nivolumab
    id
    OG000
    title
    Nivolumab Monotherapy (Expansion)
  2. description
    3 mg/kg of nivolumab and 1 mg/kg of ipilimumab Q3W for 4 doses, followed by nivolumab alone at 3 mg/kg Q2W
    id
    OG001
    title
    Nivolumab + Ipilimumab
  3. description
    3 mg/kg of nivolumab Q2W + 3 mg/kg of lirilumab Q4W
    id
    OG002
    title
    Nivolumab + Lirilumab
param Type
NUMBER
population Description
All Treated Participants
reporting Status
POSTED
time Frame
At baseline (prior to start of study treatment)
title
Number of Participants With PD-L1 Expression
type
SECONDARY
unit Of Measure
Number of Participants

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice